Market cap
$28 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 21.74 | 600.00 | 255.88 | -59.84 | -38.68 |
| EBIT | -51.30 | -99.78 | -42.70 | 2.12 | 2.20 |
| Net Profit | 36.19 | -30.54 | -31.39 | -27.95 | -198.92 |
| EPS | 36.01 | -27.81 | -468.08 | -474.99 | -336.09 |
| Book Value | -- | -- | -- | -- | 89.42 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-23 | Dec-22 | Dec-21 |
| EBIT-Margin
| -11,037.14 | -6,881.90 | -7,014.08 | -20,514.71 | -5,582.64 |
| Net Margin
| -- | -593.26 | -- | -- | -- |
| Return on equity
| 148.74 | 189.49 | 252.12 | 73.50 | 120.60 |
| Return on Capital
| -670.86 | -527.14 | -275.51 | -935.50 | -801.57 |
| Return on Assets
| -272.42 | -229.43 | -194.70 | -333.82 | -288.74 |
| Debt to Equity (x)
| -- | -- | 0.80 | -1.05 | -1.12 |
Profitability
ROCE
-275.51
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-275.51
|
-935.50
|
-801.57
|
-410.01
|
-213.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
252.12
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
252.12
|
73.50
|
120.60
|
757.49
|
-256.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-194.70
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-194.70
|
-333.82
|
-288.74
|
-193.12
|
-136.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-7,014.08
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-7,014.08
|
-20,514.71
|
-5,582.64
|
-571.25
|
-726.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-10,424.65
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-10,424.65
|
-31,394.12
|
-7,097.22
|
-574.06
|
-612.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
3.18
--
Year on year growth in net sales
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
3.18
|
-0.76
|
-0.92
|
0.08
|
0.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-42.80
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-42.80
|
13.24
|
24.66
|
15.03
|
-11.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-38.68
--
Year on year growth in profit after tax
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-38.68
|
-4.44
|
6.89
|
11.37
|
-65.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-0.39
--
Year on year growth in earnings per share
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-0.39
|
-35.72
|
0.07
|
0.12
|
-0.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.80
--
Total debt / Net worth
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
0.80
|
-1.05
|
-1.12
|
-1.23
|
0.88
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.67
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
0.67
|
-0.44
|
-0.60
|
-0.47
|
0.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.13
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
0.13
|
0.24
|
0.25
|
0.43
|
1.23
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
--
|
--
|
--
|
0.43
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-2.03
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-2.03
|
-2.09
|
-7.33
|
-21.38
|
-22.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
40.14
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
40.14
|
11.76
|
17.36
|
17.45
|
21.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.02
--
Sales / Average Total Assets
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
0.02
|
0.01
|
0.04
|
0.33
|
0.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
78.45
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
78.45
|
155.77
|
445.15
|
67.36
|
52.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
--
|
--
|
0.02
|
0.00
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
2,613.35
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
2,613.35
|
25,356.78
|
21,136.44
|
3,175.13
|
2,047.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
--
|
--
|
-20,691.27
|
-3,107.77
|
-1,994.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-0.03
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-0.03
|
-0.06
|
-4.05
|
-5.22
|
-5.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.08
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
0.08
|
-0.03
|
-3.49
|
-11.21
|
30.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.45
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
-0.45
|
-2.65
|
-7.23
|
-7.02
|
-5.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|